Compelling Impacts of Natural Polymer-Centered Drug Delivery Systems as Prophylactic and Therapeutic Approaches in Various Pulmonary Disorders/Lung Diseases

Pulmonary disorders are common illness that affects people of all ages world­wide. Common pulmonary disorders include pulmonary hypertension, CF (cystic fibrosis), asthma, chronic obstructive pulmonary disorder, emphysema, chronic bronchitis, lung cancer, and COVID-19. Treatments of these disorders vary but can be broadly categorized into pharmacological (medicinal), non-pharmacological, rehabilitation, and surgical techniques. Often, a combina­tion of these approaches is used, both for symptomatic relief and treatment. Regarding these prophylactic and therapeutic approaches, advances are rapidly being made, and scientists are currently investigating modern and unique theranostic methods. However, there is a lacuna in drug delivery, pharmacokinetic aspects, and drug-induced adverse effects. One particular area for improvement that needs to be immediately addressed is the drug delivery system to significantly improve healthcare associated with pulmonary disorders. Natural polymer-based drug delivery systems are widely adopted for their ease of production, lack of biotoxicity, and strong bioaffinity. Of the natural polymer­based drug delivery systems, chitosan, sodium alginates, albumin, hydroxyapa­tite, and hyaluronic acid are the most common natural polymers. Each of these natural polymers has its preferred use, either due to tissue-specific delivery or medical property packaging. The current scientific article discusses the common pulmonary disorders, their pathophysiology, and the current therapeutic approaches. Additionally, we discuss the major natural polymer drug delivery systems, including their properties and common uses. © The Author (s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023.

Deduced Respiratory Scores on COVID-19 Patients Learning from Exertion-Induced Dyspnea.

Dyspnea is one of the most common symptoms of many respiratory diseases, including COVID-19. Clinical assessment of dyspnea relies mainly on self-reporting, which contains subjective biases and is problematic for frequent inquiries. This study aims to determine if a respiratory score in COVID-19 patients can be assessed using a wearable sensor and if this score can be deduced from a learning model based on physiologically induced dyspnea in healthy subjects. Noninvasive wearable respiratory sensors were employed to retrieve continuous respiratory characteristics with user comfort and convenience. Overnight respiratory waveforms were collected on 12 COVID-19 patients, and a benchmark on 13 healthy subjects with exertion-induced dyspnea was also performed for blind comparison. The learning model was built from the self-reported respiratory features of 32 healthy subjects under exertion and airway blockage. A high similarity between respiratory features in COVID-19 patients and physiologically induced dyspnea in healthy subjects was observed. Learning from our previous dyspnea model of healthy subjects, we deduced that COVID-19 patients have consistently highly correlated respiratory scores in comparison with normal breathing of healthy subjects. We also performed a continuous assessment of the patient's respiratory scores for 12-16 h. This study offers a useful system for the symptomatic evaluation of patients with active or chronic respiratory disorders, especially the patient population that refuses to cooperate or cannot communicate due to deterioration or loss of cognitive functions. The proposed system can help identify dyspneic exacerbation, leading to early intervention and possible outcome improvement. Our approach can be potentially applied to other pulmonary disorders, such as asthma, emphysema, and other types of pneumonia.

Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications.

Coronavirus disease 2019 (COVID-19) causes transmissible viral illness of the respiratory tract prompted by the SARS-CoV-2 virus. COVID-19 is one of the worst global pandemics affecting a large population worldwide and causing catastrophic loss of life. Patients having pre-existing chronic disorders are more susceptible to contracting this viral infection. This pandemic virus is known to cause notable respiratory pathology. Besides, it can also cause extra-pulmonary manifestations. Multiple extra-pulmonary tissues express the SARS-CoV-2 entry receptor, hence causing direct viral tissue damage. This insightful review gives a brief description of the impact of coronavirus on the pulmonary system, extra-pulmonary systems, histopathology, multiorgan consequences, the possible mechanisms associated with the disease, and various potential therapeutic approaches to tackle the manifestations.

Role of melatonin in respiratory diseases (Review).

Melatonin, primarily secreted by the pineal gland, is an anthracemal compound. Its chemical name is N-acetyl-5-methoxytryptamine. Great advances in melatonin-related research have been made, including the understanding of its roles in the rhythm of the sleep/wake cycle, retardation of aging processes, as well as antioxidant and/or anti-inflammatory effects. Melatonin exerts a wide range of physiological effects related to the high lipophilicity of melatonin itself. Melatonin has strong radical scavenging activity, which serves an important role in pulmonary disorders. Pulmonary disorders are among the diseases that threaten human health. Especially in developing countries, due to environmental factors such as smoke and dust, the incidences of pulmonary disorders are high. Melatonin has been reported to have great potential to treat patients with pulmonary disorders. The present review discusses the relationship between melatonin and pulmonary disorders, including coronavirus disease-2019, chronic obstructive pulmonary disease, non-small cell lung cancer and pulmonary fibrosis.

Diagnosis of hypercritical chronic pulmonary disorders using dense convolutional network through chest radiography.

Lung-related ailments are prevalent all over the world which majorly includes asthma, chronic obstructive pulmonary disease (COPD), tuberculosis, pneumonia, fibrosis, etc. and now COVID-19 is added to this list. Infection of COVID-19 poses respirational complications with other indications like cough, high fever, and pneumonia. WHO had identified cancer in the lungs as a fatal cancer type amongst others and thus, the timely detection of such cancer is pivotal for an individual's health. Since the elementary convolutional neural networks have not performed fairly well in identifying atypical image types hence, we recommend a novel and completely automated framework with a deep learning approach for the recognition and classification of chronic pulmonary disorders (CPD) and COVID-pneumonia using Thoracic or Chest X-Ray (CXR) images. A novel three-step, completely automated, approach is presented that first extracts the region of interest from CXR images for preprocessing, and they are then used to detects infected lungs X-rays from the Normal ones. Thereafter, the infected lung images are further classified into COVID-pneumonia, pneumonia, and other chronic pulmonary disorders (OCPD), which might be utilized in the current scenario to help the radiologist in substantiating their diagnosis and in starting well in time treatment of these deadly lung diseases. And finally, highlight the regions in the CXR which are indicative of severe chronic pulmonary disorders like COVID-19 and pneumonia. A detailed investigation of various pivotal parameters based on several experimental outcomes are made here. This paper presents an approach that detects the Normal lung X-rays from infected ones and the infected lung images are further classified into COVID-pneumonia, pneumonia, and other chronic pulmonary disorders with an utmost accuracy of 96.8%. Several other collective performance measurements validate the superiority of the presented model. The proposed framework shows effective results in classifying lung images into Normal, COVID-pneumonia, pneumonia, and other chronic pulmonary disorders (OCPD). This framework can be effectively utilized in this current pandemic scenario to help the radiologist in substantiating their diagnosis and in starting well in time treatment of these deadly lung diseases.